Trademark: 79293279
Word
LIMINAL BIOSCIENCES
Status
Registered
Status Code
700
Status Date
Tuesday, July 20, 2021
Serial Number
79293279
Registration Number
6422386
Registration Date
Tuesday, July 20, 2021
Mark Type
3000
Filing Date
Friday, April 17, 2020
Published for Opposition
Tuesday, May 4, 2021

Trademark Owner History
Liminal BioSciences Inc. - Original Registrant

Classifications
5 Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of asthma; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of dandruff; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; anti-viral agents; antibiotics; antivirals; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hypercholesterolemia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely, diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident, stroke, Parkinson's disease, multiple sclerosis, myasthenia gravis
40 Manufacture of pharmaceuticals to the order and specification of others
42 Development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; pharmaceutical research and development; pharmaceutical research services; research on the subject of pharmaceuticals
44 Pharmaceutical advice; pharmaceutical consultancy services; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; providing information to patients in the field of administering medications; medical care services relating to patient treatment, excluding services in the field of psychology and mental health
45 Providing personal support services for families of patients with life threatening disorders, namely, emotional counseling and emotional support, and coordinating the procurement and administration of medication; providing companionship services for families of patients with life threatening disorders
The color(s) teal, light green and gray is/are claimed as a feature of the mark.
"BIOSCIENCES"
The mark consists of two interlocking incomplete triangles in gradients of teal and light green to the left of a vertical gray line and the wording "LIMINAL BIOSCIENCES" in gray. The color white represents background and is not a feature of the mark.
LIMINAL BIOSCIENCES

Trademark Events
Dec 26, 2021
Final Decision Transaction Processed By Ib
Nov 26, 2021
Final Disposition Notice Sent To Ib
Nov 26, 2021
Final Disposition Processed
Oct 20, 2021
Final Disposition Notice Created, To Be Sent To Ib
Jul 20, 2021
Registered-Principal Register
May 4, 2021
Official Gazette Publication Confirmation E-Mailed
May 4, 2021
Published For Opposition
May 2, 2021
Notification Processed By Ib
Apr 14, 2021
Notification Of Possible Opposition Sent To Ib
Apr 14, 2021
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Apr 14, 2021
Notification Of Notice Of Publication E-Mailed
Mar 29, 2021
Approved For Pub - Principal Register
Mar 29, 2021
Examiner's Amendment Entered
Mar 29, 2021
Notification Of Examiners Amendment E-Mailed
Mar 29, 2021
Examiners Amendment E-Mailed
Mar 29, 2021
Examiners Amendment -Written
Mar 22, 2021
Teas/Email Correspondence Entered
Mar 21, 2021
Correspondence Received In Law Office
Mar 21, 2021
Teas Response To Office Action Received
Oct 19, 2020
Refusal Processed By Ib
Oct 1, 2020
Non-Final Action Mailed - Refusal Sent To Ib
Sep 30, 2020
Refusal Processed By Mpu
Sep 15, 2020
Application Filing Receipt Mailed
Sep 13, 2020
Non-Final Action (Ib Refusal) Prepared For Review
Sep 12, 2020
Non-Final Action Written
Sep 11, 2020
Assigned To Examiner
Sep 11, 2020
New Application Office Supplied Data Entered In Tram
Sep 10, 2020
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24